Veraxa Biotech (VRXA) CEO Christoph Antz Buys 5,000 Shares

What Happened
Christoph Rudiger Antz, CEO of Veraxa Biotech AG (post de‑SPAC) bought 5,000 shares on August 27, 2026. The transaction was coded "P" (open market or private purchase) at $1.53 per share, for a total reported value of $7,650. This was a purchase — which investors often view as a more informative insider action than routine selling.

Key Details

• Transaction date: 2026-08-27
• Filing date (Form 4): 2026-08-31 — filed within the required 2-business-day window (timely).
• Transaction code: P (purchase — open market or private purchase)
• Shares purchased: 5,000 @ $1.53 = $7,650 total
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes/other: No 10b5-1 plan, tax withholding, or derivative activity indicated in the details provided.

Context
The dollar amount of this purchase is modest ($7.65k), so while insider buys can signal confidence, the size here is small relative to many insider trades. For retail investors, consider this data point alongside company fundamentals, recent news, and other insider activity rather than viewing it as a standalone investment signal.